53 related articles for article (PubMed ID: 32860080)
1. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
Shimokawa M; Hayashi T; Nishimura J; Satoh T; Fukunaga M; Matsui R; Tsuji Y; Mizuki F; Kogawa T
BMC Cancer; 2021 Oct; 21(1):1111. PubMed ID: 34656107
[TBL] [Abstract][Full Text] [Related]
2. Body Mass Index Affects Delayed Chemotherapy-induced Vomiting in Pediatric Malignancy Patients.
Yu L; Zhou Y; Zhang W; Wu Q; Chu X; Zhang Y; Lv D; Shen Z
J Pediatr Hematol Oncol; 2023 Oct; 45(7):398-403. PubMed ID: 37677942
[TBL] [Abstract][Full Text] [Related]
3. Age of Pediatric Patients Affects Delayed Chemotherapy-Induced Vomiting.
Zhao H; Weng J; Shi W; Pan L; Lin C; Wang N; Zhu J; Shen Z
Clin Pediatr (Phila); 2023 Oct; ():99228231206708. PubMed ID: 37881962
[TBL] [Abstract][Full Text] [Related]
4. Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis.
Zhong C; Cheng X; Jia B; Xiong P; Lu J; Zhang P; Liu X; Chen Y
Medicine (Baltimore); 2020 Nov; 99(47):e23038. PubMed ID: 33217804
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Cicali B; Lingineni K; Cristofoletti R; Wendl T; Hoechel J; Wiesinger H; Chaturvedula A; Vozmediano V; Schmidt S
CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):48-58. PubMed ID: 33217171
[TBL] [Abstract][Full Text] [Related]
6. Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease.
Toychiev A; Navruzov B; Pazylova D; Davis N; Badalova N; Osipova S
Acta Trop; 2021 Jan; 213():105755. PubMed ID: 33188747
[TBL] [Abstract][Full Text] [Related]
7. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis.
Weibel S; Schaefer MS; Raj D; Rücker G; Pace NL; Schlesinger T; Meybohm P; Kienbaum P; Eberhart LHJ; Kranke P
Anaesthesia; 2021 Jul; 76(7):962-973. PubMed ID: 33170514
[TBL] [Abstract][Full Text] [Related]
8. Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".
Affronti ML; Herndon JE; Patel MP
Support Care Cancer; 2020 Dec; 28(12):5591-5592. PubMed ID: 32885313
[No Abstract] [Full Text] [Related]
9. Dexamethasone Stimulation Test in the Diagnostic Work-Up of Growth Hormone Deficiency in Childhood: Clinical Value and Comparison With Insulin-Induced Hypoglycemia.
Cattoni A; Molinari S; Medici F; De Lorenzo P; Valsecchi MG; Masera N; Adavastro M; Biondi A
Front Endocrinol (Lausanne); 2020; 11():599302. PubMed ID: 33362716
[TBL] [Abstract][Full Text] [Related]
10. Application of comprehensive unit-based safety program model to improve chemotherapy-induced nausea and vomiting in patients with ovarian cancer: a retrospective study.
Liu A; Li M; Liu Z; Xie X; Yao W; Wang J; Zhao T; Yang J
J Ovarian Res; 2023 Jul; 16(1):143. PubMed ID: 37468962
[TBL] [Abstract][Full Text] [Related]
11. Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients.
Li N; Lu J; Xia D; Jiang X; Wen X; Qin X; Chen Y; Wang T
J Gastrointest Oncol; 2022 Feb; 13(1):197-209. PubMed ID: 35284113
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301).
Takei S; Ishibe A; Watanabe J; Watanabe K; Suwa Y; Suzuki S; Nakagawa K; Suwa H; Ota M; Ichikawa Y; Kunisaki C; Yamanaka T; Endo I
Int J Colorectal Dis; 2020 Dec; 35(12):2323-2329. PubMed ID: 32860080
[TBL] [Abstract][Full Text] [Related]
17. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
